Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Crocs, Inc. (CROX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Crocs, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.87 (market cap $4.49B), while Crocs, Inc. trades at $124.38 (market cap $6.19B). The key difference: Crocs, Inc. is the larger of the two by market cap, and Crocs, Inc. is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | CROX | |
|---|---|---|
Market Cap | $4.49B | $6.19B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $127.77 |
52-Week Low | $20.06 | $73.39 |
Enterprise Value | $3.69B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Crocs (CROX) trades at $124.55, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $4.04B for 2025 but posted a net loss of $81.20M, with negative profit margins. Recent earnings have consistently beaten expectations, and analyst sentiment remains positive with a 51.35% buy rating and consensus price target of $131.75. News highlights include marketing initiatives like TikTok microdramas and expansion in Asian markets.
The outlook for CROX is mixed: strong brand momentum and earnings beats support upside potential, but profitability concerns and negative net income margins pose risks. Investors should weigh growth initiatives against margin pressures and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
